相关临床试验
476
154 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
16
3.4%
已完成
35
7.3%
Enrolling By Invitation
7
1.5%
尚未招募
131
27.5%
招募中
165
34.7%
暂停
2
0.4%
Unknown
117
24.6%
撤回
3
0.6%
暂无批准数据
- The ALTER-L043 phase II trial demonstrated that perioperative penpulimab plus anlotinib and chemotherapy achieved a 76.0% major pathological response rate in resectable NSCLC patients, compared to 57.7% with penpulimab plus chemotherapy alone. - All three treatment combinations showed manageable safety profiles with no treatment-related deaths, though immune-related adverse events were more common in the triple combination group (36.7% vs 20.0% vs 23.3%). - The study represents the first randomized analysis of perioperative immunotherapy combined with an antiangiogenic agent in resectable NSCLC, with particularly promising results in patients with squamous histology and stage IIIA/IIIB disease.
- A Chinese-developed drug combination of Benmelstobart and Anlotinib demonstrated superior efficacy over pembrolizumab (Keytruda) in treating PD-L1-positive advanced non-small cell lung cancer patients. - The combination therapy increased median progression-free survival by 3.9 months to 11 months total, with a 30% reduction in disease progression and death risk compared to the current standard treatment. - Results from the Phase III CAMPASS study involving over 500 patients were presented at the American Society of Clinical Oncology annual meeting as a Late-Breaking Abstract. - The achievement marks a potential shift from Chinese pharmaceutical companies being followers to leaders in international cancer treatment development.
- A phase 2 trial demonstrates that combining camrelizumab immunotherapy with induction chemotherapy and chemoradiotherapy achieved an 84% 3-year disease-free survival rate in advanced nasopharyngeal cancer patients. - The treatment regimen showed particularly strong efficacy in patients with high tumor burden (T4 or N3 stage), with 80% of nasopharyngeal lesions and 100% of lymph nodes achieving complete response after treatment. - The combination therapy demonstrated manageable safety profile, with most adverse events being well-tolerated and no unexpected severe toxicities reported.
- A phase 2 trial in China demonstrated that pyrotinib combined with metronomic vinorelbine is effective in HER2-positive advanced breast cancer patients after trastuzumab failure. - The combination therapy achieved a median progression-free survival of 13.5 months and an overall response rate of 38.9% in the studied patient population. - The treatment regimen showed a manageable safety profile, with the most common adverse events being diarrhea, nausea, and vomiting, and no grade 4/5 events reported. - Researchers suggest this dual-oral regimen is a feasible option where antibody-drug conjugates are not readily accessible, warranting further investigation in larger trials.
